title: The use of conjugated hyperbilirubinemia greater than 100 micromol/L as an indicator of irreversible liver disease in infants with short bowel syndrome.
abstract: BACKGROUND
  The introduction of parenteral nutrition resulted in improved survival of neonates with short bowel syndrome. It is unclear why some may deteriorate to end-stage liver disease (ESLD). Knowledge of when to refer such children for evaluation for transplantation is crucial. A commonly used criterion is conjugated hyperbilirubinemia greater than 100 micromol/L (CB100).
  
  
  OBJECTIVE
  The aim of this study is to evaluate if CB100 is a reliable marker for identifying which infants with short bowel syndrome will subsequently develop ESLD.
  
  
  METHODS
  All neonates from our short bowel registry (1997-2003) were reviewed. Conjugated hyperbilirubinemia greater than 100 micromol/L was defined as a sustained CB100 for at least 2 weeks with no concurrent sepsis. The sensitivity, specificity, as well as positive and negative predictive values for predicting an outcome of ESLD were calculated.
  
  
  RESULTS
  Seventy short gut infants were identified (25 males; mean gestational age of 32.5 +/- 4.9 weeks and weight of 1902 +/- 888 g). Twenty-three patients (33%) developed CB100. Seventeen patients (24%) developed ESLD. Conjugated hyperbilirubinemia greater than 100 micromol/L had a sensitivity of 94% and a specificity of 87% in determining which patients would advance to ESLD. The positive and negative predictive values were 70% and 98%, respectively. The median time from CB100 to ESLD was 60 days (range, 10-365 days).
  
  
  CONCLUSIONS
  A positive predictive value of 70% ensures a safe level of over-triage to the transplant service for assessment; however, the short duration from CB100 to ESLD (60 days) implies a late detection of advanced liver disease, which raises concern about the use of this test in the clinical setting.
authors.affiliation: Division of General Surgery, Faculty of Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada M5G 1X8.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Nasr
authors.forename: Yaron
authors.initials: Y
authors.lastname: Avitzur
authors.forename: Vicky L
authors.initials: VL
authors.lastname: Ng
authors.forename: Nicole
authors.initials: N
authors.lastname: De Silva
authors.forename: Paul W
authors.initials: PW
authors.lastname: Wales
mesh_terms: D001663:Bilirubin / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006801:Humans; D051556:Hyperbilirubinemia, Neonatal / Q000150:complications* / Q000401:mortality; D007223:Infant; D007231:Infant, Newborn; D017093:Liver Failure / Q000209:etiology* / Q000401:mortality / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D011237:Predictive Value of Tests; D011336:Probability; D011379:Prognosis; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012778:Short Bowel Syndrome / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D015996:Survival Rate
chemical_list: D015415:Biomarkers; D001663:Bilirubin